Ccris 6547 | 138147-78-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Ccris 6547
• 英文别名: (2S)-N-[(2S)-1-[[1-[[(2S)-1-[[2-[[(2S)-1-[[1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methylpentan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(3R)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl]amino]pentanediamide
• CAS: 138147-78-1
• 化学式: C₅₆H₇₉N₁₅O₉
• 分子量: 1106.3
• InChiKey: IUYCRRDHLJIJBB-XBSVZSNVSA-N

物化性质

• 沸点：
  1547.9±65.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  80
• 可旋转键数：
  30
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  374
• 氢给体数：
  14
• 氢受体数：
  12

文献信息

• Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
  申请人：AEterna Zentaris GmbH

  公开号：EP1900742A1

  公开（公告）日：2008-03-19

  The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and/or pathophysiological conditions in mammals, in particular for the treatment of various tumors.

  本发明提供了二氢异菊烯酮及其衍生物与细胞结合分子（如肽、蛋白质、激素、血液蛋白和抗体）结合的共轭物。本发明还提供了新的二氢异菊烯酮衍生物及制造这些共轭物和二氢异菊烯酮衍生物的方法。这些化合物可用作治疗哺乳动物的生理和/或病理状况，特别是治疗各种肿瘤的药物。
• THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME
  申请人：Yamano Mayumi

  公开号：US20090093415A1

  公开（公告）日：2009-04-09

  [Problem]To provide a therapeutic agent for irritable bowel syndrome (IBS), which is excellent in efficacy and safety. [Means for Resolution]It was shown that the bombesin 2 (BB2) receptor antagonists typified by RC-3095 are therapeutic agents for irritable bowel syndrome (IBS), which show excellent efficacy in both of an abdominal symptom and bowel movement disorder. Thus, according to the present invention, it became possible to provide a therapeutic agent for irritable bowel syndrome (IBS) which comprises, as an active ingredient, a bombesin 2 (BB2) receptor antagonist exerting an excellent efficacy in both an abdominal symptom and bowel movement disorder.

  [问题] 提供一种治疗肠易激综合症（IBS）的治疗剂，其疗效和安全性均优秀。 [解决方法] 证明以RC-3095为代表的炸弹素2（BB2）受体拮抗剂是治疗肠易激综合症（IBS）的治疗剂，其在腹部症状和肠道运动障碍方面均表现出优异的疗效。因此，根据本发明，可以提供一种治疗肠易激综合症（IBS）的治疗剂，其包含作为活性成分的炸弹素2（BB2）受体拮抗剂，在腹部症状和肠道运动障碍方面表现出优异的疗效。
• CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF
  申请人：Æterna Zentaris GmbH

  公开号：EP2066679A1

  公开（公告）日：2009-06-10
• US7741277B2
  申请人：——

  公开号：US7741277B2

  公开（公告）日：2010-06-22
• US8101580B2
  申请人：——

  公开号：US8101580B2

  公开（公告）日：2012-01-24